Keywords
cidofovir, anti-viral, pediatric, adenovirus, stem-cell, solid organ, immunocompromised
cidofovir, anti-viral, pediatric, adenovirus, stem-cell, solid organ, immunocompromised
Adenovirus (ADV) is a common cause of respiratory infection in childhood. ADV infections are usually self-limited and asymptomatic in the immunocompetent host but have been recognized as a cause of significant morbidity and mortality in immunocompromised pediatric patients such as recipients of hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT)1. In these patients, ADV is an opportunistic pathogen that may lead to severe localized disease including pneumonia/pneumonitis, hepatitis, hemorrhagic cystitis or disseminated disease with multiorgan failure2–4. Case fatality rates in immunocompromised patients with ADV pneumonia have been reported to be as high as 60%5. Currently, there is no FDA-labeled product available for treatment of ADV infection though several agents have been administered for this indication including ribavirin6,7, ganciclovir8, vidarabine9,10, immune globulin11 and cidofovir12–21.
Cidofovir (CDV), a nucleoside and phosphonate analogue is a broad-spectrum antiviral agent that inhibits viral DNA polymerase and has broad activity in vitro against multiple viruses including all serotypes of ADV22,23. CDV has an FDA indication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. Although this drug does not have an FDA indication for treating ADV, there is evidence of in vivo efficacy of CDV against ADV12,14. While CDV at a standard dose of 5mg/kg has been reported as primary therapy for treatment of ADV infection in pediatric and adult hematopoietic stem cell transplantation (HSCT) patients12,21, concern exists regarding potential nephrotoxicity. These associated adverse effects have limited the use of CDV for treatment of ADV infections in pediatric patients. To minimize potential toxicity of CDV, modified dosing regimens such as the use of 1 mg/kg three times have been utilized14.
Limited information regarding safety and efficacy of CDV in pediatric patients prompted us to review prior published studies in the literature and conduct a retrospective review of our inpatient use of CDV at Boston Children’s Hospital (BCH).
Following Institutional Review Board (IRB) approval (IRB-P00015576), a retrospective chart review was conducted for all hospitalized patients at Boston Children’s Hospital (BCH), who were prescribed CDV for adenovirus infection from January 2006 through December 2010. The following data were collected: (1) demographic information, (2) underlying disease state, (3) type of transplant, (4) duration of cidofovir therapy, (6) serum creatinine (SCr) (baseline, peak during therapy, and level up to 2 weeks post last dose), (7) concomitant nephrotoxins prescribed (acyclovir, amikacin, cyclosporine, foscarnet, gentamicin, liposomal amphotericin B, tacrolimus, tobramycin, vancomycin, and intravenous contrast media), (8) sites of ADV detection by viral direct fluorescent antibody (DFA), nucleic acid test, and/or culture, (9) viral quantitative PCR surveillance in blood and other sites of infection (all specimens were tested at least weekly before, during and to two weeks post last dose of CDV to evaluate for changes in viral load with a minimum three serial values being obtained before, during and at end of therapy); (10) symptoms of infection, and clinical course including response to therapy, (11) concomitant reduction of immunosuppression and (12) mortality and cause(s) of mortality. All blood sample testing for adenovirus quantitative PCR in blood was performed at the Boston Children’s Hospital Virology Laboratory using our laboratory developed test, the Argene adenovirus assay (bioMerieux, Cambridge, MA). The Argene adenovirus assay contains primers and probes selective for a 138 base pair (bp) sequence in the Hexon gene of the adenovirus. Using a 5’ nuclease assay, viral DNA is detected using the primers and fluorescent probes from the Argene assay kit by means of real time PCR in a Cepheid SmartCycler (Cepheid, Sunnyvale, CA).
As there is no accepted definition for ADV infection or disease, we adopted definitions used in prior studies13. Specifically, definite adenovirus disease as follows: Non-gastrointestinal locations: Symptoms and signs from the appropriate organ combined with histopathological documentation of adenovirus and/or adenovirus detection by culture, antigen test, or nucleic acid test from biopsy specimens (liver or lung), BAL fluid, or cerebrospinal fluid and without another identifiable cause; Gastrointestinal location: Symptoms together with detection of adenovirus from biopsy material by culture, antigen test, or nucleic acid test.
Probable adenovirus disease as follows: Gastrointestinal tract: Detection of adenovirus in stool by culture, antigen test, or nucleic acid test together with symptoms; Urinary tract: Symptoms of dysuria or hematuria combined with detection of adenovirus by culture, antigen test, or nucleic acid test without another identifiable cause; and Respiratory tract: Symptoms and signs of pneumonia/pneumonitis combined with detection of adenovirus by culture, antigen test, or nucleic acid test without another identifiable cause.
Asymptomatic adenovirus infection as follows: any detection of adenovirus in an asymptomatic patient from stool, blood, urine, or upper airway specimens by viral culture, antigen tests, or PCR.
Adenoviremia was defined as the detection of >100 copies of ADV/mL of blood (this being the lower limit of detection of the assay). Viral clearance was defined as an ADV viral load of <100 copies in blood by quantitative PCR at the end of therapy. Viral response was defined as decrease in viremia by at least one log-fold. Clinical resolution was defined as resolution of symptoms and/or signs of infection. Renal dysfunction was defined as a ≥50% increase in SCr from baseline during the course of CDV therapy. The peak SCr during therapy was used to calculate the number of patients that experienced renal dysfunction.
Statistical analyses employed Prism 5 for Windows Version 5.04 (GraphPad Software Inc, CA). The Mann-Whitney test was used to assess risk of renal dysfunction. Trends in adenoviremia including pre-treatment viral load, changes in viral load during therapy, and post-treatment viral load were graphed.
From January 1, 2006 to December 31, 2010, a total of 16 pediatric patients received CDV for adenovirus infection at our hospital. These 16 patients received 19 courses (three patients received two separate CDV courses). The standard CDV dose of 5mg/kg weekly was used in all courses unless there was concern for renal dysfunction at the start of therapy in which case a dosing regimen of 1mg/kg three times a week was used. Patient demographics, primary diagnosis, clinical symptoms and course, and sites of adenovirus detection appear in Table 1. Patient age ranged from 0.75–20 years (mean 6.5 years). Seven (44%) patients were male. Underlying primary diagnosis included 8 (50%) HSCT (1 autologous), 4 (25%) SOT, 2 (12.5%) leukemia, and 2 (6.5%) defined as other. Duration of CDV therapy ranged from 5–82 days (median 33.5 days).
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CID, congenital immunodeficiency; CML, chronic myelogenous leukemia; HLH, hemophagocytic lymphohistiocytosis; MRD, matched related donor; MUD, matched unrelated donor; Pt #, patient number; SCID, severe combined immunodeficiency disorder; SCT, stem cell transplant; UD, unrelated donor; Yrs, years; Site of adenovirus detection: S, stool, Sp, sputum, B, blood, BAL, bronchoalveolar lavage, R, respiratory DFA, CSF, cerebrospinal fluid, U, Urine, PF, Pericardial Fluid; *indicates patient expired
Of the 19 courses prescribed (Table 1), two courses were prescribed in a patient with definite adenovirus disease of the gastrointestinal tract, 15 courses were prescribed in patients with probable disease and two courses were prescribed in patients with asymptomatic infection. Sixteen courses (84%) were in patients who had a positive blood ADV PCR either in whole blood only or in combination with positive ADV PCR of sputum, stool, urine, broncho-alveolar lavage (BAL) fluid, pericardial fluid or positive sputum adenoviral DFA sample. Respiratory symptoms were the most common presentation in 10 courses (53%) of which six courses were prescribed for patients with respiratory symptoms and radiological evidence of pneumonia. Two courses were prescribed in patients who presented with prolonged fevers; four courses were prescribed in patients who had worsening diarrhea and colitis, two of which were biopsy proven adenovirus infection; four courses were prescribed in patients with viral sepsis with or without pneumonia; and two courses were administered in patients with severe hemorrhagic cystitis. Two courses were prescribed in patients with asymptomatic respiratory tract infection and asymptomatic gastrointestinal infection respectively.
We further examined the 16 blood-positive courses to assess trends in ADV viral load pre-, during and post- CDV therapy (Figure 1). A quantitative reduction in viral load was seen in 15 blood positive courses (94%) with viral clearance achieved in 14 (88%). Of note, all solid organ transplant recipients treated with CDV also had concomitant decrease in their immunosuppression. A single patient (Patient 6) did not demonstrate viral response to therapy and expired. The majority of adenovirus blood-positive CDV courses (10/16, 63%) were associated with clinical improvement with viral clearance, however this was not the case in four courses. Patients 7, 10, 11 and 16 expired despite demonstrating viral clearance. Patients 6, 7 and 16 had multiple other co-infections. Patients 11 and 16 developed severe hemorrhagic cystitis. Patient 11 experienced significant complications of hemorrhagic cystitis including urinary tract obstruction, renal failure and bladder perforation. Patient 16 also had concomitant BK Polyoma virus detected in the urine.
Each patient’s medication profile was assessed to determine the number of additional nephrotoxic agents concomitantly prescribed during CDV therapy (from Day 1 to 7 days post last CDV dose). All 19 courses prescribed had at least one additional nephrotoxic agent prescribed during CDV therapy (Table 2). Four courses (21%) had only one additional nephrotoxic medication prescribed, five courses (26%) had two such medications prescribed, six courses (32%) had three prescribed, two courses (11%) had four prescribed, and two courses (11%) had five prescribed.
Administration of CDV was significantly associated with occurrence of renal dysfunction when comparing the peak Cr measured during CDV therapy to the baseline serum Cr (p=0.0016). Eleven courses (58%) were associated with development of renal dysfunction. Cr increased by a mean of ~50% from baseline during CDV therapy (Figure 2). Of the courses with elevation in serum creatinine, 64% demonstrated return to pre-treatment creatinine levels following cessation of CDV therapy. There was no statistically significant difference when assessing for increased risk of renal dysfunction if patients received ≤ 1 additional nephrotoxic agent or ≥ 2 additional nephrotoxic agents.
In this retrospective review of patients treated with CDV for adenovirus infection at our hospital during a 5-year period, we assessed the safety and potential efficacy of the medication in pediatric patients. Our review yielded a case series of 16 patients. While the number of patients is modest, this series adds to the existing literature describing the use of CDV in pediatric recipients of HSCT, SOT and chemotherapy for oncologic diagnoses (Table 3).
Study | # Patients (N) | Clinical Setting | Median Age | Cidofovir dosage | Duration of cidofovir use | Potential Toxicity | Outcome |
---|---|---|---|---|---|---|---|
Hoffman14 | 8 | HSCT | 7 yrs | 1 mg/kg/dose three times weekly × 9 doses or until clearance | 3 weeks–8 months | Well tolerated; no toxicity reported | 100% viral suppression 3 recurrences 4 expired (2 ADV- related) |
Muller12 | 10 | HSCT | Not reported | 5 mg/kg/dose weekly up to 6 weeks, then every other week for 3 more doses | 3 weeks–6 months | 30% nephrotoxicity (50% increase Cr) | 9 virologic clearance 5 recurrences 1 expired (interstitial pneumonitis) |
Anderson19 | 7 | HSCT | 1.5 yrs | Preemptive therapy: 1 mg/kg/dose three times weekly × 3 weeks | 3 weeks | Well tolerated without significant toxicity reported | No patient developed ADV viremia 2 expired (non-ADV related) |
Bhadri15 | 23 | 87% HSCT 13% oncologic receiving chemotherapy | 5.7 yrs | 5 mg/kg/dose weekly, 3 mg/kg/dose weekly or 1 mg/kg/dose three times weekly | Median 6 weeks (1–26 weeks) | 9% Grade 1 nephrotoxicity defined by increase of creatinine up to 1.5 times upper limit of normal | 85% of 20 evaluable patients considered successful by Ljungman criteria13 17 expired |
Yusuf17 | 57 | 90% HSCT 10% oncologic receiving chemotherapy | 8 yrs | 5 mg/kg/dose weekly × 2 weeks, then every other week until 3 negative ADV samples | Median 60 days (1 week–9 months) | No toxicity reported | 98% successful viral clearance 14% recurrence 29 expired (1 ADV- related death) |
Legrand18 | 7 | HSCT | 6.4 yrs | 5 mg/kg/dose weekly × 3 wks then every other wk or 10 days | 25–330 days | 43% nephrotoxicity | 71% deemed recovered 2 expired (1 ADV related death) |
Sivaprakasam26 | 8 | HSCT | 11 yrs | 1 mg/kg/dose 3 times weekly (4 patients also received IV ribavirin 5 mg/kg 3 times daily) | Not reported | 2 cases marrow failure, 1 case nephropathy | 3 expired (attributed to ADV and GVHD) |
Williams27 | 9 | HSCT | 3 yrs | 5 mg/kg/dose once weekly until 3 weeks of negative results or pt no longer high risk; if underlying renal dysfunction 1 mg/kg/ dose 3 times weekly | Median 8 doses (3–32 doses) | 22% renal failure (compared to 80% untreated comparator group) | 89% ADV clearance 3 expired (1 ADV related) |
Engelmann16 | 1 | Liver transplant | 7 months | 6 mg/kg/dose × 1 with 1 repeat dose 6 days later | 2 weeks | No toxicity reported | Liver rejection; reported to have slow recovery |
Wallot20 | 2 | Liver transplant | 8 months and 14 months | 1 mg/kg/dose three times weekly | 5–8 weeks | 1 moderate neutropenia, 1 transient rise in creatinine | Blood PCR ADV clearance in both patients No deaths |
Carter24 | 1 | Liver transplant | 7 months | 1 mg/kg/dose three times weekly | 7 weeks | Transient acidosis and proteinuria | ADV viral culture and blood PCR became negative |
Doan25 | 4 | Lung transplant | <3 yrs | 1 mg/kg/dose every other day to three times weekly plus IVIG (1 pt increased dose to 2 mg/kg/dose; 1 pt increased frequency to daily therapy × 2 weeks) | 4 weeks | No toxicity reported | 75% negative blood ADV PCR 1 death |
Similar to other studies the majority of our patients had received a HSCT or had an oncologic diagnosis and received chemotherapy. We identified eight publications describing the use of CDV for adenovirus infection in the setting of HSCT or oncologic diagnoses treated with chemotherapy (Table 3). Three of these studies14,17,27 reported viral clearance in 89–100% of their patients. We observed similar rates of viral clearance (88%) but this was not consistently associated with clinical improvement.
There are very few reports on the use of CDV for adenovirus infection in pediatric SOT recipients, which have largely been restricted to reports of children receiving liver or lung transplants16,20,24,25. We identified four publications reporting the use of CDV for adenovirus infection in pediatric SOT recipients limited to one to four per report and all of these children having received liver or lung transplants16,20,24,25. Doan et al.25 described children who had received lung transplants with reported viral clearance in three of their four patients. Our case series contributes patients who received several types of SOT including lung, heart, combined kidney and liver, and multi-visceral transplants. All patients with SOT in our series demonstrated viral clearance as well as resolution of symptoms, which may have reflected a combination of both the antiviral effect of CDV coupled with reduced immunosuppression.
Two-thirds of our patients experienced resolution of their symptoms and had an overall favorable clinical course with recovery. However, one-third died all of which were stem cell transplant recipients. With the exception of one patient it is unclear whether adenovirus was the direct cause of mortality in these patients. Our observations are consistent with what has been reported in the literature pertaining to outcomes in stem cell transplant recipients with adenovirus infections who have been treated with CDV9,12,14,18,23,27. Among SCT patients mortality remains high (10%–70%) even when clearance from blood is seen.
In our case series, renal dysfunction was common during CDV therapy with patients experiencing an average 50% increase of serum creatinine from their baseline. However, renal dysfunction was transient in the majority of patients with serum creatinine returning to baseline after cessation of CDV therapy. While some studies have reported no toxicities related to the use of CDV14,16,17,19,25, the transient nature of nephrotoxicity observed has been reported by other studies20,24. We were unable to detect any increased risk of nephrotoxicity associated with concomitant administration of additional nephrotoxic agents but this may reflect our small number of study participants.
Our study has several limitations. Most notably, the small number of patients precluded evaluation of other factors that may impact infection resolution such as immunosuppressive regimens, and additional factors that may impact degree of renal dysfunction. Nevertheless, our study adds to the limited reported literature of pediatric ADV patients treated with CDV.
F1000Research: Dataset 1. Raw data for Figure 1, 10.5256/f1000research.8374.d11732128
F1000Research: Dataset 2. Raw data for Figure 2, 10.5256/f1000research.8374.d11732229
OL conceived the study. LG, AA and SJ collected data and prepared the first draft of the manuscript. LG, AP and DG performed data analysis. MH contributed to the preparation of the manuscript. All authors were involved in the revision of the draft manuscript and have agreed to the final content.
OL’s laboratory is supported by a Boston Children’s Hospital Department of Medicine award to the Precision Vaccines Program as well as Global Health (OPPGH5284) and Grand Challenges Explorations (OPP1035192) awards from the Bill & Melinda Gates Foundation and by NIH grants 1R01AI100135-01 and 3R01AI067353- 05S1 and National Institute of Allergy & Infectious Diseases Adjuvant Discovery Program, Contract No. HHSN272201400052C. The Levy Laboratory has received sponsored research support from VentiRx Pharmaceuticals, 3M Drug Delivery Systems, MedImmune, and Crucell (Johnson & Johnson)- companies that develop adjuvants and vaccines.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
References
1. Bhadri VA, Lee-Horn L, Shaw PJ: Safety and tolerability of cidofovir in high-risk pediatric patients.Transpl Infect Dis. 2009; 11 (4): 373-9 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 2 (revision) 16 Dec 16 |
read | ||
Version 1 26 Apr 16 |
read | read | read |
Click here to access the data.
Spreadsheet data files may not format correctly if your computer is using different default delimiters (symbols used to separate values into separate cells) - a spreadsheet created in one region is sometimes misinterpreted by computers in other regions. You can change the regional settings on your computer so that the spreadsheet can be interpreted correctly.
Click here to access the data.
Spreadsheet data files may not format correctly if your computer is using different default delimiters (symbols used to separate values into separate cells) - a spreadsheet created in one region is sometimes misinterpreted by computers in other regions. You can change the regional settings on your computer so that the spreadsheet can be interpreted correctly.
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Toth et al. 2008. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci U S A 105:7293-7297.
Diaconu et al. 2010. Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. Journal of Gene Medicine 12:435-445.
Ying et al. 2014. Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters. Antimicrob Agents Chemother 58:7171-7181.
Tollefson et al. 2014. Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model. Antiviral Res 112:38-46.
Toth et al. 2015. Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters. Viruses 7:1409-1428.
Toth et al. 2008. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci U S A 105:7293-7297.
Diaconu et al. 2010. Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. Journal of Gene Medicine 12:435-445.
Ying et al. 2014. Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters. Antimicrob Agents Chemother 58:7171-7181.
Tollefson et al. 2014. Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model. Antiviral Res 112:38-46.
Toth et al. 2015. Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters. Viruses 7:1409-1428.